1 week ago
Vir Biotechnology (VIR) Stock Jumps 13% After Phase 3 Hepatitis Delta Win
TLDR Vir Biotechnology stock rose 13% to $13.85 on Monday. Phase 3 ECLIPSE 1 met its primary and key secondary endpoints. 44% of treated patients had undetectable virus and normal ALT at Week 48, versus 0% for delayed treatment. One Grade 3 treatment-related event was reported, and no patient stopped treatment. Phase 2 SOLSTICE data [...]
The post Vir Biotechnology (VIR) Stock Jumps 13% After Phase 3 Hepatitis Delta Win appeared first on Blockonomi.
Source: Blockonomi →Related News
- 41 minutes ago
Nvidia tops estimates, issues strong guidance; shares rise
- 41 minutes ago
Microsoft Corporation (MSFT) Stock: Fall 2.37% Despite Major AI Security Initia...
- 1 hour ago
KIDZ AI Inc. (KIDZ) Stock: Eyes Growth Through Synestria GPU Computing Partnersh...
- 1 hour ago
Vertiv Holdings (VRT) Stock: Expands 800 VDC Power Systems for AI Data Centers
- 2 hours ago
Coinbase CEO says AI agents will account for '99.9%' of transactions within a de...
